4593.T Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 02:15):

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States...

Stats
Today's Volume	511 900
Average Volume	1.43M
Market Cap	13.07B
EPS	¥0 ( 2024-02-13 )
Next earnings date	( ¥-4.96 ) 2024-05-09
Last Dividend	¥0 ( N/A )
Next Dividend	¥0 ( N/A )
P/E	-2.58
ATR14	¥0.236 (0.16%)

Volume Correlation

Long: -0.08 (neutral)

Short: 0.81 (strong)

Signal:(63.052) Same movement expected

Healios K.K. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Healios K.K. Correlation - Currency/Commodity

-0.15
( neutral )

-0.27
( neutral )

0.00
( neutral )

-0.35
( neutral )

0.51
( weak )

0.14
( neutral )

Healios K.K. Financials

Annual	2023
Revenue:	¥121.00M
Gross Profit:	¥-265.00M (-219.01 %)
EPS:	¥-56.22

Q4	2023
Revenue:	¥7.00M
Gross Profit:	¥80.00M (1 142.86 %)
EPS:	¥-23.22

Q3	2023
Revenue:	¥7.00M
Gross Profit:	¥-70.00M (-1 000.00 %)
EPS:	¥-9.98

Q2	2023
Revenue:	¥100.00M
Gross Profit:	¥87.00M (87.00 %)
EPS:	¥-10.37

Financial Reports:

No articles found.

Healios K.K.

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration; HLCL041, an iPSC regenerative medicine for the treatment of metabolic liver disease; and HLCM051, a regenerative medicine for treatment of ischemic stroke and acute respiratory distress syndrome, as well as HLCN061 for treating solid tumors. Healios K.K. has a joint research agreement with the Hyogo Medical University on cancer immunotherapies for mesothelioma using eNK cells. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.